Physician profile
Madison Beardmore
NPI 1225713951
$754.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $299 · 2024: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.32 | 2023-2024 | Repatha, Otezla |
| Genzyme Corporation | $113.75 | 2024 | |
| Edwards Lifesciences Corporation | $98.42 | 2023 | |
| Abbvie INC. | $75.26 | 2023-2024 | |
| Lilly USA, LLC | $66.24 | 2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $47.92 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $40.97 | 2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $33.10 | 2023-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $31.26 | 2023-2024 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $26.56 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $23.81 | 2024 | Keveyis |
| Astellas Pharma US INC | $18.77 | 2024 | Veozah |
| Neurocrine Biosciences, INC. | $18.63 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Beardmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.